BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matza LS, Sapra SJ, Dillon JF, Kalsekar A, Davies EW, Devine MK, Jordan JB, Landrian AS, Feeny DH. Health state utilities associated with attributes of treatments for hepatitis C. Eur J Health Econ 2015;16:1005-18. [PMID: 25481796 DOI: 10.1007/s10198-014-0649-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Walter E, Berger T, Bajer-Kornek B, Deisenhammer F. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria. J Med Econ 2019;22:226-37. [PMID: 30522373 DOI: 10.1080/13696998.2018.1556668] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Steen Carlsson K, Andersson E, Berntorp E. Preference-based valuation of treatment attributes in haemophilia A using web survey. Haemophilia 2017;23:894-903. [PMID: 28851125 DOI: 10.1111/hae.13322] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
3 Tejwani R, Wang HS, Lloyd JC, Kokorowski PJ, Nelson CP, Routh JC. Utility Estimation for Pediatric Vesicoureteral Reflux: Methodological Considerations Using an Online Survey Platform. J Urol 2017;197:805-10. [PMID: 27746280 DOI: 10.1016/j.juro.2016.09.119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 De Abreu Lourenco R, Haas M, Hall J, Viney R. Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence. Pharmacoeconomics 2017;35:347-62. [PMID: 27858368 DOI: 10.1007/s40273-016-0470-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Rentz AM, Mansukhani SG, Liu J, Lloyd AJ, Heidenreich S, Matza LS, Dawson NA, Shore N, Freedland SJ. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation. Urol Oncol 2021;39:367.e7-367.e17. [PMID: 33736976 DOI: 10.1016/j.urolonc.2020.12.014] [Reference Citation Analysis]
6 Saad F, Fleshner NE, So A, Le Lorier J, Perrault L, Poulin-Costello M, Rogoza R, Robson EJD. The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres. Can Urol Assoc J 2018. [PMID: 29940132 DOI: 10.5489/cuaj.5053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Matza LS, Chung KC, Kim KJ, Paulus TM, Davies EW, Stewart KD, McComsey GA, Fordyce MW. Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation. Qual Life Res 2017;26:1785-98. [PMID: 28341926 DOI: 10.1007/s11136-017-1519-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Matza LS, Stewart KD, Davies EW, Hellmund R, Polonsky WH, Kerr D. Health State Utilities Associated with Glucose Monitoring Devices. Value in Health 2017;20:507-11. [DOI: 10.1016/j.jval.2016.10.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
9 Elsisi GH, Aburawash A, Waked E. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective. Value Health Reg Issues 2017;13:7-15. [PMID: 29073993 DOI: 10.1016/j.vhri.2017.03.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
10 Matza LS, Brazier JE, Stewart KD, Pinto L, Bender RH, Kircik L, Jordan J, Kim KJ, Mutebi A, Viswanathan HN, Menter A. Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI). J Med Econ 2019;22:936-44. [PMID: 31161828 DOI: 10.1080/13696998.2019.1627362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
11 Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison LP Jr. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. J Med Econ 2020;23:501-12. [PMID: 31971453 DOI: 10.1080/13696998.2020.1721508] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
12 Mattingly TJ 2nd, Perfetto EM, Johnson SL. Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review. Hepatology 2018;67:774-81. [PMID: 28834597 DOI: 10.1002/hep.29482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ballinger R, Macey J, Lloyd A, Brazier J, Ablett J, Burden S, Lal S. Measurement of Utilities Associated with Parenteral Support Requirement in Patients with Short Bowel Syndrome and Intestinal Failure. Clinical Therapeutics 2018;40:1878-1893.e1. [DOI: 10.1016/j.clinthera.2018.09.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
14 Dusheiko G. The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. Liver Int. 2017;37 Suppl 1:7-12. [PMID: 28052638 DOI: 10.1111/liv.13292] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
15 Rattanavipapong W, Anothaisintawee T, Teerawattananon Y. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. PLoS One 2018;13:e0193112. [PMID: 29466415 DOI: 10.1371/journal.pone.0193112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hendriks S, Pearson SD. Assessing potential cures: are there distinctive elements of value beyond health gain? J Comp Eff Res 2021. [PMID: 33663230 DOI: 10.2217/cer-2020-0190] [Reference Citation Analysis]
17 Matza LS, Deger KA, Howell TA, Koetter K, Yeager AM, Hogge D, Fisher V, Louie AC, Chung KC. Health state utilities associated with treatment options for acute myeloid leukemia (AML). J Med Econ 2019;22:567-76. [PMID: 30775943 DOI: 10.1080/13696998.2019.1584108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Matza LS, Boye KS, Jordan JB, Norrbacka K, Gentilella R, Tiebout AR, Browne C, Orsini Federici M, Biricolti G, Stewart KD. Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. Patient Prefer Adherence 2018;12:971-9. [PMID: 29922043 DOI: 10.2147/PPA.S159620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast Cancer Res Treat 2016;159:565-73. [DOI: 10.1007/s10549-016-3958-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
20 Visser LA, Folcher M, Delgado Simao C, Gutierrez Arechederra B, Escudero E, Uyl-de Groot CA, Redekop WK. The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing-Remitting Multiple Sclerosis. Pharmacoeconomics 2021. [PMID: 34480325 DOI: 10.1007/s40273-021-01081-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Matza LS, Kim KJ, Yu H, Belden KA, Chen AF, Kurd M, Lee BY, Webb J. Health state utilities associated with post-surgical Staphylococcus aureus infections. Eur J Health Econ 2019;20:819-27. [PMID: 30887157 DOI: 10.1007/s10198-019-01036-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Matza LS, Boye KS, Stewart KD, Davies EW, Paczkowski R. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Serv Res 2017;17:774. [PMID: 29178918 DOI: 10.1186/s12913-017-2648-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
23 Davies EW, Llewellyn S, Beaudet A, Kosmas CE, Gin-Sing W, Doll HA. Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. Patient Prefer Adherence 2018;12:1079-88. [PMID: 29950821 DOI: 10.2147/PPA.S160662] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
24 Lin S, Luo S, Gu D, Li M, Rao X, Wang C, Huang P, Xu X, Weng X. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis. Oncologist 2021;26:e2013-20. [PMID: 34431578 DOI: 10.1002/onco.13954] [Reference Citation Analysis]
25 Matza LS, Paramore LC, Stewart KD, Karn H, Jobanputra M, Dietz AC. Health state utilities associated with treatment for transfusion-dependent β-thalassemia. Eur J Health Econ 2020;21:397-407. [PMID: 31828456 DOI: 10.1007/s10198-019-01136-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Lin S, Luo S, Zhong L, Lai S, Zeng D, Rao X, Huang P, Weng X. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. Int J Clin Pharm 2020;42:1175-83. [DOI: 10.1007/s11096-020-01076-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
27 Matza LS, Stewart KD, Lloyd AJ, Rowen D, Brazier JE. Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. Value Health 2021;24:812-21. [PMID: 34119079 DOI: 10.1016/j.jval.2020.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Matza LS, Cutts KN, Stewart KD, Norrbacka K, García-Pérez LE, Boye KS. Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Qual Life Res 2021;30:2033-43. [PMID: 33886044 DOI: 10.1007/s11136-021-02808-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Uy J, Ketkar AG, Portnoy A, Kim JJ. Cost-utility analysis of heart surgeries for young adults with severe rheumatic mitral valve disease in India. Int J Cardiol 2021;338:50-7. [PMID: 34090957 DOI: 10.1016/j.ijcard.2021.05.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Salans M, Courtney PT, Yip A, Murphy JD. Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma. Cancer Med 2021. [PMID: 34402192 DOI: 10.1002/cam4.4194] [Reference Citation Analysis]
31 Aviles-Blanco MV. Economic evaluation of process utility: elucidating preferences for a non-invasive procedure to treat restenosis. Health Econ Rev 2021;11:27. [PMID: 34297212 DOI: 10.1186/s13561-021-00327-x] [Reference Citation Analysis]